Fractional Flow Reserve (FFR)


Original Research



Round Table Discussions


ORBITA: What Goes Around, Comes Around… Or Does It?

Medical therapy has been the primary treatment for stable angina since nitroglycerin was first used in 1878. However, since the first successful percutaneous coronary intervention (PCI) procedure was performed in 1977, the role of PCI in patients with stable coronary artery disease (CAD) has been the subject of much study. Numerous trials have shown no reduction in death or myocardial infarction.1–5 However, these trials suggest that PCI is maybe more effective for managing angina symptoms than medical therapy alone.

FFRCT for Complex Coronary Artery Disease Treatment Planning: New Opportunities

Coronary CTA has rapidly gone from a test with potential to be considered a first-line test for patients with stable chest pain.1 It provides robust ability to exclude atherosclerosis and coronary artery stenosis and more recently has been shown to inform and guide clinical treatment making in a fashion that enables a reduction in myocardial infarction when compared to traditional stress testing.2–5 Despite the growing clinical utility data and continued technology improvements, re

Assessing the Haemodynamic Impact of Coronary Artery Stenoses: Intracoronary Flow Versus Pressure Measurements

The emphasis in ischaemic heart disease (IHD) diagnosis has historically been directed towards the identification of epicardial coronary stenosis by selective coronary angiography, and its management by percutaneous coronary intervention (PCI) or coronary bypass graft surgery.

Advances in Coronary Physiology: Update for 2017

Coronary artery disease (CAD), the most common cause of morbidity and mortality in the US, is frequently identified by coronary angiography. Decisions for treatment are often based on angiography alone, absent other clinical indicators for intervention. However, by angiography alone, conventional wisdom has suggested that a coronary stenosis is significant if there is at least a 50 % diameter reduction in the left main coronary artery, or at least a 70 % diameter reduction in any other epicardial artery.

Performing and Interpreting Fractional Flow Reserve Measurements in Clinical Practice: An Expert Consensus Document

The invasive measurement of fractional flow reserve (FFR) can determine the haemodynamic relevance of coronary artery stenoses. Determination of FFR is recommended in coronary artery stenoses with a luminal diameter narrowing between 50 % and 90 % if no non-invasive proof of ischaemia is available.1 To measure the FFR of a given coronary lesion, a wire or a microcatheter equipped with a miniaturised pressure sensor is inserted into the coronary artery.